Physician profile
Leslie Ann Lee
NPI 1285623058
$8,075.73
in general payments reported to CMS, 2019-2025
30 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,896 · 2022: $1,148 · 2023: $1,835 · 2024: $2,026 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,032.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,423.77 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $1,256.35 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $993.95 | 2021-2025 | |
| Abbott Laboratories | $695.84 | 2022-2025 | Freestyle Libre |
| Novo Nordisk INC | $647.25 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.23 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $375.01 | 2021-2025 | Shingrix, Arexvy |
| Amgen INC. | $339.76 | 2021-2024 | Repatha, Prolia, Evenity |
| Abbvie INC. | $325.77 | 2021-2024 | |
| Dexcom, INC. | $219.07 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $179.59 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.06 | 2022-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $151.77 | 2022-2024 | |
| Inspire Medical Systems, INC. | $123.78 | 2023-2025 | Inspire |
| Exact Sciences Corporation | $120.62 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $116.98 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $92.78 | 2021-2022 | |
| Genzyme Corporation | $64.82 | 2023-2025 | |
| Eisai INC. | $60.61 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $55.20 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $48.63 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $43.10 | 2023 | Contrave, Onzetra Xsail |
| Otsuka America Pharmaceutical, INC. | $26.76 | 2023-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $26.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.21 | 2024 | Voquezna |
| Boston Scientific Corporation | $19.22 | 2024 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $16.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.26 | 2021 | |
| Amarin Pharma, INC. | $15.15 | 2021 | |
| Medtronic, INC. | $13.68 | 2025 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.